Pharmaceutical Technology Is Now PharmTech: A Sharper Name for a Smarter Industry

Navigating FDA Shakeups and Obesity Drug Wars

Behind the Headlines Episode 28

Ask the Expert

Outsourcing Partnerships Fuel Global Biopharma Discovery and Scale-Up

Drug Digest February 2026 

How It Helps Avoid Facility and Equipment Problems

A “Plan, Prevent, Prove” Approach

Senior Content Associate For Pharmaceutical Commerce

Los Angeles, USA - December 1, 2022 Eli Lilly only editorial Stock information on the logo of the office facade | © StockMarketVisuals - stock.adobe.com

The FDA has approved Foundayo (orforglipron), Eli Lilly's once-daily oral small-molecule GLP-1 receptor agonist for chronic weight management, marking a pivotal shift in how peptide-independent obesity therapies can be developed and scaled.

 Unlike existing injectable GLP-1 biologics, orforglipron's non-peptide structure eliminates the formulation and cold-chain complexities that have historically challenged GLP-1 manufacturing, opening new pathways for oral solid dose production at commercial scale.

Orforglipron is the first new molecular entity cleared under the FDA's Commissioner's National Priority Voucher (CNPV) pilot program, with a review completed in just 50 days, the fastest NME approval since 2002.

 This signals a meaningful shift in FDA throughput capacity and sets a new benchmark for accelerated NME review timelines.

"This approval demonstrates what the FDA can achieve when we eliminate delays and prioritize fast and thorough work from the agency and industry partners," said FDA Commissioner Martin Makary, MD, MPH, in a press release.

The CNPV program now represents a concrete, and precedent-backed, mechanism for compressing time-to-approval without compromising review rigor.

How Can Foundayo Advance GLP-1 Access and Ease of Use?

A primary focus of the Foundayo launch is addressing the practical barriers that have historically limited the adoption of GLP-1 therapies. While injectable GLP-1 medications have seen high demand, the complexity of administration and strict fasting requirements for existing oral options have posed challenges for long-term adherence. Foundayo distinguishes itself as the only GLP-1 pill that can be taken at any time of day without specific food or water restrictions.

The clinical community suggests that this flexibility could be a decisive factor in improving patient outcomes. Deborah Horn, DO, director of the Center for Obesity Medicine, McGovern Medical School at UTHealth Houston, noted the importance of treatment options that align with patient lifestyles. “People living with obesity need treatment options that meet them where they are – and for many, a once-daily pill that can be taken with no food or water restrictions can offer them greater flexibility in how they approach their treatment,” Horn said.

According to David A. Ricks, chair and CEO, Eli Lilly, current utilization of GLP-1s remains low relative to the population that could benefit, citing “fewer than 1 in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity or the belief that their condition isn't serious enough for treatment.”

“We believe Foundayo can help level the playing field for those living with obesity or who are overweight and living with weight-related complications,” Ricks said.

What Does Orforglipron's Clinical Package Mean for Small-Molecule GLP-1 Development?

The ATTAIN clinical trial program, spanning more than 4,500 participants, delivered the efficacy data needed to support orforglipron's approval and, critically, validates the small-molecule GLP-1 receptor agonist as a commercially viable therapeutic class.

In the 72-week ATTAIN-1 trial, the highest dose achieved 12.4% mean weight loss versus 0.9% in the placebo group, with additional improvements across cardiovascular risk markers including systolic blood pressure, triglycerides, and waist circumference. This breadth of endpoints strengthens the case for pursuing small-molecule GLP-1 candidates across cardiometabolic indications beyond obesity.

From a formulation and dosing strategy perspective, orforglipron's titration schedule offers instructive design insights.

 Starting at 0.8 mg and escalating every 30 days, through 2.5 mg and 5.5 mg, to a maximum of 17.2 mg, the regimen was built to manage gastrointestinal tolerability and sustain long-term adherence. This stepwise dose escalation reflects deliberate decisions around release profile, tablet strength flexibility, and the need to manufacture across a wide dose range within a single oral solid dose platform. Considerations that must be resolved early in process development.

Higher adherence rates associated with once-daily oral dosing also carry downstream implications for clinical trial design and commercial forecasting.

 Reduced dropout rates driven by route-of-administration preferences can strengthen trial powering assumptions and support more robust long-term safety datasets, a benefit that compounds across Phase III programs and post-market commitments.

How Will Lilly Provide Access to Foundayo?

To facilitate broad access, Eli Lilly announced that Foundayo will be available through LillyDirect with free home delivery starting April 6, 2026.

 The company has also introduced a pricing structure aimed at reducing out-of-pocket costs. Eligible patients with commercial insurance may pay as little as $25 per month, while those opting for self-pay can access the medication starting at $149 per month. Additionally, coverage for eligible Medicare Part D individuals is expected to begin in July 2026.

What Are the Potential Side Effects of Foundayo?

Foundayo’s safety profile is consistent with the GLP-1 receptor agonist class. Common side effects reported in clinical trials include nausea, constipation, diarrhea, vomiting, and abdominal pain.

 The drug’s labeling includes a boxed warning regarding the risk of thyroid C-cell tumors. Patients with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 are advised against using the medication. Other warnings include potential risks for pancreatitis, acute gallbladder disease, and hypoglycemia when used with certain other medications.

The FDA’s acting CDER director Tracy Beth Høeg, MD, PhD, affirmed the rigor of the review process despite the expedited timeline. “The approval of orforglipron is another example of how the FDA’s CNPV pilot program has been able to more quickly bring effective treatments to Americans. Individuals who are overweight or obese now have an additional option to help with weight loss — a GLP-1 receptor partial agonist pill which does not need to be taken on an empty stomach,” Høeg said.

The FDA plans to hold a public meeting on June 4, 2026, to discuss the ongoing implementation and criteria of the CNPV program following this historic first NME approval.

U.S. Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program. Published April 1, 2026. Accessed April 1, 2026. 

https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program

Eli Lilly and Company. FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. Published April 1, 2026. Accessed April 1, 2026. 

https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill

Articles

FDA approval of Foundayo (orforglipron), a once-daily oral small-molecule GLP-1 receptor agonist for chronic weight management, establishes a scalable, peptide-independent path for GLP-1 therapy manufacturing and distribution. As the first new molecular entity cleared via the FDA Commissioner’s National Priority Voucher pilot, the 50-day review sets a modern benchmark for expedited approvals without stated compromise in rigor. Clinical data from the ATTAIN program support meaningful weight loss and cardiometabolic improvements, while simplified administration may improve adherence and broaden real-world uptake.

The FDA approves orforglipron (Foundayo), the first oral, non-peptide GLP-1 for obesity, the fastest NME approval under the new CNPV program.

FDA's 50-Day NME Approval Changes Drug Development Rules

Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a transaction valued at approximately $6.3 billion upfront, with an additional $1.5 billion in potential milestone payments tied to regulatory approvals.

 The deal gives Lilly full ownership of Centessa's pipeline of orexin receptor 2 agonists, a class of compounds designed to directly modulate the neurobiological system governing the sleep-wake cycle.

The acquisition signals meaningful commercial and scientific momentum behind orexin receptor biology, a target area that has attracted growing attention following the clinical success of orexin antagonists in insomnia.

 Where that earlier wave focused on blocking the pathway to promote sleep, Centessa's compounds take the opposite approach, activating the receptor to restore wakefulness in patients whose orexin signaling is impaired or absent.

Centessa's lead compound, cleminorexton, has completed Phase IIa studies across narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.

 The pipeline also includes additional clinical and preclinical-stage assets with potential utility in neurodegenerative and neuropsychiatric conditions.

"Orexin receptor biology represents one of the most compelling mechanistic opportunities in neuroscience as a direct intervention on the master switch of the sleep-wake cycle. Centessa has assembled a portfolio with the breadth and depth to improve wakefulness across a broad array of indications," said Carole Ho, executive vice president and president of Neuroscience, Lilly, stated in a press release.

 "Joining forces with Centessa colleagues means we can now pursue that potential at the speed and scale it deserves."

What Does This Mean for Drug Development Timelines and Regulatory Strategy?

Lilly is paying $38.00 per share in cash at closing, plus a non-transferable contingent value right worth up to $9.00 per share, for a total potential per-share consideration of $47.00.

 The contingent payments are tied to three specific milestones: $2.00 upon FDA approval of cleminorexton or ORX142 for narcolepsy type 2 before the fifth anniversary of closing; $5.00 upon FDA approval of either compound for idiopathic hypersomnia within the same window; and $2.00 upon the first FDA approval of either compound for any indication before January 1, 2030. The upfront cash represents a roughly 40.5% premium to Centessa's 30-day volume-weighted average trading price as of March 30, 2026.

The milestone structure reflects the regulatory complexity still ahead.

 Idiopathic hypersomnia in particular remains an area with limited approved treatments and evolving diagnostic criteria, factors that development and regulatory affairs teams will be tracking closely as Lilly advances these programs. The January 2030 hard deadline on one of the contingent payments adds a concrete timeline pressure that will shape how Lilly prioritizes its clinical execution post-close.

Mario Alberto Accardi, chief executive officer, Centessa and founder of the orexin program, stated in the press release.

 "By combining Centessa's team and capabilities with Lilly's global complementary research, clinical, regulatory and commercial capabilities, we will seek to accelerate the advancement of our orexin portfolio across a broad range of neuroscience indications for the benefit of patients in need."

The acquisition will be carried out through a scheme of arrangement under the laws of England and Wales.

 It requires approval from Centessa's shareholders and sanction from the High Court of Justice of England and Wales, in addition to standard regulatory clearances. Shareholders representing approximately 24.1% of Centessa's outstanding ordinary shares have already signed voting and support agreements committing to approve the transaction.

The post-close integration will be a key area to watch.

 Centessa's pipeline is still largely in clinical stages, meaning chemistry, manufacturing, and controls strategies, supply chain buildout, and process development work for commercial-scale manufacturing remain ahead. How Lilly integrates Centessa's scientific team and institutional knowledge of the orexin program will determine how quickly these compounds can move through the pipeline and ultimately reach patients.

 "Driven by a bold vision, our team has advanced an innovative portfolio with the speed, rigor and conviction needed to lead a new era of orexin-based therapeutics. This milestone reflects not only the strength of our science, but also the transformative potential of our orexin portfolio for patients who urgently need new solutions."

Is Lilly Building a Broader Neuroscience and Immunology Platform?

The Centessa acquisition is not an isolated move.

 Just days earlier, Lilly presented Phase IIIb data showing that combining its biologic Taltz with its obesity medication Zepbound delivered statistically superior outcomes in adults managing both psoriatic arthritis and obesity, a population representing roughly 65% of patients with psoriatic arthritis in the United States. The trial met its primary and all key secondary endpoints at 36 weeks, with improvements spanning disease activity, fatigue, physical function, and cardiometabolic markers. Together, these developments suggest Lilly is deliberately expanding into complex, comorbidity-driven patient populations where single-mechanism therapies have historically fallen short.

Eli Lilly and Company and Centessa Pharmaceuticals plc. Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders. Indianapolis (IN) and Boston (MA) and London (UK): Eli Lilly and Company and Centessa Pharmaceuticals plc; 2026 Mar 31. Available from: 

https://investors.centessa.com/news-releases/news-release-details/lilly-acquire-centessa-pharmaceuticals-advance-treatments-sleep

Eli Lilly and Company. Phase 3b data presented at AAD Annual Meeting show Lilly’s Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity. Indianapolis (IN): Eli Lilly and Company; 2026 Mar 28. Available from: 

https://investor.lilly.com/news-releases/news-release-details/phase-3b-data-presented-aad-annual-meeting-show-lillys-taltz

Lilly acquires Centessa for $6.3B, gaining an orexin receptor agonist pipeline targeting narcolepsy and other sleep-wake disorders.

Why Lilly Paid $6.3 Billion for Sleep Science

Workplace modern laboratory for molecular biology test | Image Credit: ©JacobST - stock.adobe.com

The European Medicines Agency (EMA) announced on March 31, 2026 that it’s Committee for Medicinal Products for Human Use (CHMP) has issues a draft qualification opinion

 for a preclinical research methodology to reduce the use of animals in specific dose-range finding studies.

 The new approach method (NAM) would replace standard animal control groups with virtual groups, and once qualified, would allow CHMP to accept evidence generated from virtual control groups in medicine approval applications.

EMA states that reduction in animal testing will be gradual. The first qualification opinion for a NAM used in toxicity assessment will create a “blueprint” for future applications, and potential versions of the NAM could be qualified in the future for toxicological studies that require routine control groups. “Replacing control groups with ‘virtual animals’ in such studies would have a substantial impact on reducing the total numbers of animals used,” the agency stated in the press release.

To create a virtual control group, control data are characterized, and appropriate virtual comparator animals are identified, in line with a standard operating procedure and a statistical approach complemented by expert judgement.

The use of virtual control groups is part of EMA’s and the International Coalition of Medicines Regulatory Authorities’ commitment to replace, reduce, and refine the use of animals in the development and regulation of drugs. According to the agency, NAMs can contribute to these efforts, and the agency supports the integration of NAMs into various mechanisms to enable regulatory acceptance and foster innovation without the use of animals.

“Through the integration of virtual control groups, EMA also seeks to improve the relevance and predictability of non-clinical testing, which supports both more efficient and more ethically responsible medicines development,” the agency stated in the release.

 “A key requirement for the implementation of virtual control groups is the assurance that their use does not compromise study outcomes or pose a threat to human safety in later clinical trials.”

Public consultation on the draft opinion is open from March 31 through May 12, 2026. Input from the scientific community and stakeholders can be sent to 

How Is FDA Making Similar Moves in the US?

On March 18, 2026, FDA issued a draft guidance document on how to validate NAMs to replace animal testing in drug development.

 The document provides recommendations for validating NAMs when nonclinical NAMs data are provided.

 Drug sponsors are required to submit nonclinical pharmacology and toxicology data before an investigational drug can go to clinical trial.

The guidance document established 4 validation principles:

Context of use that provides a clear definition of the NAMs’ intended regulatory purpose

Human biological relevance to demonstrate how NAMs can assess toxicity

Technical characterization to establish scientific confidence through robust, reliable, and reproducible methods

Fit-for-purpose to provide assurance that NAMs help in regulatory decision-making (eg, drug review and potential approval).

“Technological advances are allowing us to move beyond animal testing in drug development, which has a poor track record of predicting safety and efficacy in humans,” said FDA Commissioner Marty Makary, MD, MPH, in a press release.

 “This guidance will facilitate the adoption of modern alternatives to animal testing in regulatory submissions.”

Draft Qualification opinion for Virtual Control Groups (VCG) to replace Concurrent Control Groups (CCG) in rat non-GLP Dose-Range Finding (DRF) studies. EMA. March 31, 2026. Accessed April 1, 2026. 

https://www.ema.europa.eu/en/documents/other/draft-qualification-opinion-virtual-control-groups-vcg-replace-concurrent-control-groups-ccg-rat-non-glp-dose-range-finding-drf-studies_en.pdf

EMA consults on virtual control groups to help reduce animal use in medicines development. EMA. Press release. March 31, 2026. Accessed April 1, 2026. 

https://www.ema.europa.eu/en/news/ema-consults-virtual-control-groups-help-reduce-animal-use-medicines-development

FDA releases draft guidance on alternatives to animal testing in drug development. FDA. Press release. March 18, 2026. Accessed April 1, 2026. 

https://www.fda.gov/news-events/press-announcements/fda-releases-draft-guidance-alternatives-animal-testing-drug-development

General considerations for the use of new approach methodologies in drug development. Draft guidance.

 FDA. March 19, 2026. Accessed April 1, 2026. 

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-considerations-use-new-approach-methodologies-drug-development

The agency has issued a draft qualification opinion on a new preclinical research methodology.

EMA Seeks Opinion on Animals Used in Drug Development

Melanie Cerullo is chief quality officer at Kindeva.

Pharmaceutical factory woman worker in protective clothing operating production line in sterile environment | Image Credit: ©Ivan Traimak -stock.adobe.com. Background: Canva

The 2023 revision of Annex 1 of the European Union’s good manufacturing practice (GMP) guidelines

 represents a fundamental shift in expectations for sterile manufacturing. Regulators now expect a comprehensive, risk-based contamination control strategy (CCS) that is actively managed across the product lifecycle. It requires manufacturers to demonstrate how sterility assurance is designed, governed, executed, monitored, and continuously improved.

For pharmaceutical and biotechnology companies, particularly for those with lean internal manufacturing capabilities or evolving sterile pipelines, Annex 1 raises the bar for oversight, data integration, and risk management. Meeting these expectations depends on technical compliance supported by disciplined execution, mature systems, and a clear operating model for contamination control.

In this article, the author explores how the revised EU GMP Annex 1 is reshaping expectations and how collaboration with expert sterile manufacturing contract development and manufacturing organizations (CDMOs) can help pharmaceutical and biotechnology companies ensure the highest level of sterility assurance for patient safety.

How Has Annex 1 Changed the Mindset for Sterility Assurance?

The revised Annex 1 marks a deliberate move from prescriptive requirements to a performance-based framework centered on prevention. Manufacturers are expected to demonstrate that controls are scientifically justified, integrated across systems, and routinely evaluated for effectiveness.

To meet these requirements, a compliant CCS must explain how facilities, equipment, utilities, materials, personnel, and processes work together to control risk. It must also demonstrate how risks are reassessed as products, volumes, and technologies change, which can be challenging for sponsor companies that are new to sterile manufacturing or managing complex pipelines.

These expectations elevate contamination control from a procedural requirement to a strategic discipline. This shift connects quality, engineering, microbiology, and operations through shared accountability and data-driven decision-making.

Sponsors face the following key challenges as they adapt to Annex 1’s expanded expectations:

Lifecycle continuity. Contamination control must be maintained from early clinical manufacture through commercial production. For companies outsourcing development, this means ensuring continuity of risk management and documentation across multiple external partners and sites.

Limited internal sterile capability. Many organizations rely on CDMOs for aseptic capability and may lack the internal expertise or capacity to redesign processes, retrain staff, or upgrade facilities for Annex 1 compliance across their portfolio.

Fragmented data systems. Effective CCS management depends on comprehensive and integrated data. Disconnected systems limit visibility and make trend analysis, which is paramount for an effective CCS, more difficult.

Resource demands. Maintaining CCS discipline over time requires sustained cross-functional engagement that can strain internal teams.

These realities are driving many companies to seek manufacturing partners that can provide both execution capability and structured contamination control frameworks.

How Can External Expertise Be Leveraged for Contamination Control?

External partners that specialize in sterile manufacturing can provide both the depth and breadth of experience required to successfully implement Annex 1. By operating across multiple delivery platforms, including injectables, pulmonary, nasal, and dermal systems, CDMO partners must continuously refine their understanding of contamination risks and controls — a distinct benefit for sponsors navigating sterility challenges. Each project adds to a collective knowledge base that can be applied across modalities, accelerating learning and driving continuous improvement in sterility assurance.

A CDMO with sterile fill-finish expertise and facilities can help sponsors meet Annex 1 expectations in the following ways:

Establishing and maintaining a harmonized CCS framework that aligns risk assessment, monitoring, and control activities across all stages of development and commercial stages.

Providing facility designs, environmental monitoring programs, and aseptic processesaligned with global regulatory expectations

Leveraging digital quality systems to integrate data from deviations, corrective and preventive action (CAPA), change control, and environmental monitoring into a unified risk profile.

Embedding contamination control culture through training, behavioral standards, and management oversight.

Enabling transparency through shared access to CCS-relevant data, supporting sponsor oversight, and regulatory confidence.

When executed well, this approach reduces uncertainty, supports inspection readiness, and strengthens sterility assurance.

How Is a Living Contamination Control Strategy Designed?

A compliant CCS must function as an operational system, not a static reference. Controls should be actively managed, monitored, and adjusted based on risk and performance. Mature organizations maintain risk registers that link each process step to potential contamination sources and defined control measures. These registers are reviewed routinely using data from environmental monitoring, process simulations, deviations, and change management.

As products scale or processes evolve, controls must evolve with them. Cross-functional teams spanning engineering, microbiology, quality, and operations are crucial to help anticipate change and prevent failures.

Digital infrastructure supports this approach by connecting quality management system (QMS) and manufacturing execution system (MES) data for trending across batches, shifts, and campaigns, enabling earlier identification of risk signals. Dashboards and automated alerts support timely decision-making and documented effectiveness reviews.

Advanced analytics and predictive tools may further enhance this capability when used to inform scientific judgment.

For sponsors, partnering with a CDMO that already has this infrastructure in place can dramatically shorten implementation timelines and help reduce quality uncertainties.

Annex 1 places structured risk management at the center of contamination control. For outsourced manufacturing, this requires a common methodology and language between the sponsor and CDMO.

Standardized tools, such as failure mode and effects analysis (FMEA), support consistent risk identification, evaluation, and mitigation. Transparency into how risks are assessed and controlled allows sponsors to demonstrate appropriate oversight while leveraging the CDMO’s operational expertise.

However, even with strong systems, human behavior remains a critical variable. Disciplined execution, strong training, and clear expectations help control risk.

Organizations with mature contamination control cultures reinforce three fundamentals:

Patient centricity is a clear understanding that every action directly affects patient safety.

Operational excellence is a commitment to performing each task consistently and seeking continual improvement.

Knowledge and risk management is the habit of questioning, learning, and sharing insights to prevent recurrence.

. Annex 1 explicitly links contamination control to the product lifecycle. Early engagement during development enables risks to be addressed upstream before qualification and scale-up. As programs mature, commercial data should be fed back into the CCS to refine controls and confirm robustness.

Digital collaboration tools, including shared QMS platforms and secure data portals, support effective oversight without slowing execution. Regular joint reviews ensure alignment and timely decision-making.

Continuous Improvement and Turning Insights into Action

To remain effective across the product lifecycle, a CCS must be actively improved using data that is collected, analyzed, and acted upon systematically. When sponsors and CDMOs take a proactive approach to data, continuous improvement becomes a natural outcome.

Harmonized key performance indicators (KPIs) such as environmental monitoring trends, aseptic process simulation success rates, deviation recurrence, and CAPA timeliness create a shared language for quality. Standardizing these metrics across sites enables meaningful benchmarking, supports early recognition of emerging risks, and highlights areas of excellence that can be replicated across programs.

To translate KPIs into meaningful change, sponsors and CDMOs need structured, collaborative reviews that turn data into action. Regular cross-functional CCS discussions can transform learnings from individual projects into enterprise-wide improvements. This approach promotes transparency, strengthens partnerships, and creates a cycle of knowledge sharing that benefits every product and every patient.

Annex 1 sets a higher standard for sterility assurance, one that is proactive, science-based and continuously managed. Organizations that treat the CCS as a static compliance document will struggle to meet regulatory expectations.

Experienced sterile manufacturing partners can accelerate Annex 1 readiness by providing disciplined frameworks, integrated data systems and operational expertise. The most effective partnerships treat contamination control as a shared responsibility supported by active risk management.

When this approach is embedded, Annex 1 drives stronger processes, safer products, and sustained regulatory confidence, supporting safe and consistent manufacturing for the people who rely on these medicines.

EC. Annex 1 Revision - Manufacture of Sterile Medicinal Products. The Rules Governing Medicinal Products in the European Union Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use. August 2022. 

https://health.ec.europa.eu/document/download/e05af55b-38e9-42bf-8495-194bbf0b9262_en?filename=20220825_gmp-an1_en_0.pdf

Melanie Cerullo, Chief Quality Officer, Kindeva

Contract development and manufacturing organizations can assist sponsor company is ensuring sterility assurance in alignment with the EU’s Annex 1 guidelines.

Is Your Annex 1 Strategy a Static Document or a Dynamic Defense?

Lilly & Insilico Collab on AI-Generated Discovery | Created with Canva

A collaboration between Insilico Medicine and Eli Lilly marks one of the most structurally significant partnerships to emerge from the intersection of generative AI and pharmaceutical development.

 Under the agreement, Lilly receives an exclusive worldwide license to develop, manufacture, and commercialize a portfolio of novel oral therapeutics currently in preclinical development across multiple indications, candidates that Insilico characterizes as potentially best-in-class. Beyond the licensed portfolio, the two organizations will jointly pursue additional research and development programs, with Lilly selecting the targets and Insilico contributing its Pharma.AI platform infrastructure alongside Lilly's clinical expertise and disease-area knowledge.

The financial structure of the deal offers a rough calibration of how the market is valuing mature artificial intelligence platforms in this space.

 Insilico is eligible to receive an upfront payment of $115 million, with development, regulatory, and commercial milestones that could bring the total value to approximately $2.75 billion, plus tiered royalties on future sales. These figures reflect not just the licensed assets themselves, but the perceived productivity of the underlying platform.

Why Does the Underlying Technology Architecture Matter to Development Teams?

Insilico's approach centers on generative AI applied across the full drug discovery workflow, from target identification through candidate generation.

 Alex Zhavoronkov, founder and chief executive, Insilico, said in a press release,

 "By deploying frontier AI technologies that scale from biomarkers to life models, world models of human and animal life, we can identify multi-purpose targets driving multiple diseases at the same time."

For scientists and project teams navigating complex biology with limited resources, this kind of multi-target identification capability has practical implications, particularly in therapeutic areas where disease mechanisms remain poorly understood or where repurposing potential is underexplored.

Andrew Adams, group vice president of Molecule Discovery, Lilly, stated in the press release,

"This collaboration allows us to explore novel mechanisms and accelerate the identification of promising therapeutic candidates across multiple disease areas."

The pairing of a platform built for generative molecular design with an organization that has deep clinical development infrastructure raises a question: whether this model, platform company plus established developer, becomes a more common structure for moving AI-generated candidates through the pipeline.

Zhavoronkov stated, in the press release,

"Working with Lilly, we aim to deliver transformative therapies that treat diseases with high unmet need. This collaboration is a testament to the power of AI in tackling the most complex challenges in human health."

Whether or not that framing proves out, the deal represents a concrete test case. The preclinical programs now moving under Lilly's development capabilities will, over time, generate real data on how AI-discovered candidates perform as they advance.

What Is Insilico's Track Record with Other Pharma Products?

Insilico reported that newly signed agreements across 2025 totaled $1.3 billion, bringing cumulative collaboration value to $4.6 billion.

 This figure spans drug discovery services, out-licensing arrangements, and co-development structures with more than ten multinational and domestic biopharmaceutical firms.

The commercial growth has run alongside continued platform investment.

 Insilico's software offering now serves 13 of the top 20 global pharmaceutical companies by revenue, with software revenue growing 23.8% year-over-year. Those numbers suggest the underlying technology is being adopted as operational infrastructure, not simply evaluated as a novelty.

On the pipeline side, the organization nominated six new preclinical candidates during 2025 and advanced eight programs in clinical development, including the first clinical proof-of-concept for an AI-discovered drug.

 That milestone carries weight beyond Insilico specifically. It represents the first peer-reviewed, published demonstration that a candidate generated end-to-end by an AI platform can produce meaningful clinical signals.

Insilico Medicine. Insilico Medicine announces global R&D collaboration with Lilly. Cambridge (MA): Insilico Medicine; 2026 Mar 29 [cited 2026 Mar 31]. Available from: 

https://insilico.com/news/uiy12zcjg1-insilico-medicine-announces-global-rampd

Insilico Medicine. Insilico Medicine announces 2025 annual results, redefining AI-driven drug discovery and development. Cambridge (MA): Insilico Medicine; 2026 Mar 29 [cited 2026 Mar 31]. Available from: 

https://insilico.com/news/ohz9ozx0t1-insilico-medicine-announces-2025-annual

Lilly licenses Insilico's AI drug discovery platform in a deal worth up to $2.75B, signaling a shift in how novel therapeutics are identified.

What Lilly’s $2.75B Bet on AI-Discovered Drug Candidates Means for Drug Development

During the past several years, AI use in pharma has expanded well beyond molecule discovery. The strongest momentum is now appearing in the operational core of the industry: process development, manufacturing execution, quality systems, and supply chain. Industry analysis indicates that AI applications could create between $350 billion and $410 billion in annual value for pharma this year alone, with manufacturing and supply chain among the most impacted functions.

This shift is occurring alongside a broader push toward digital manufacturing. FounderNest data show that digital twins and virtual manufacturing are among the fastest-growing AI technology segments, while manufacturing execution systems (MES) represent the largest process area for AI adoption over the last year.

For pharma, the question is no longer whether AI will reach manufacturing, but how quickly companies can translate digital capabilities into durable process advantage.

Patent Clusters Show Where Innovation Is Concentrating

Our patent analysis has identified three dominant innovation clusters duirng the last five years:

Continuous manufacturing and automated flow chemistry

AI-driven synthesis and laboratory automation

Advanced formulation science, including polymorph and particle engineering

These clusters are increasingly converging. Continuous manufacturing relies on enhanced monitoring and control; AI-driven synthesis platforms are extending from route design into lab execution and process optimization; and formulation development is becoming more model-driven, reducing empirical iteration during scale-up.

Our data also show that AI and digital twins are now being embedded directly into manufacturing systems. Examples include:

Digital process twins combining simulation with ML-based “soft sensors” to estimate critical quality attributes in real time

Event-driven control systems integrating live process data into automated decision loops

AI-assisted and AR-enabled batch record systems that streamline QA documentation

The broader implication is clear: process intelligence itself is becoming patentable infrastructure.

Growth in AI-Related Pharma Patents Remains Strong

Using patent intelligence data from the FounderNest platform, alongside funding, partnership, and deployment signals across the market, Felix Gonzalez highlights where AI and digital technologies are gaining traction in pharmaceutical development and manufacturing, and what it means for competition this year.

Featured Content

Pharmaceutical Technology Is Now PharmTech: A Sharper Name for a Smarter Industry

Behind the Headlines Episode 28

Ask the Expert

Drug Digest February 2026

A “Plan, Prevent, Prove” Approach